DAN inhibitors refer to a class of molecules that specifically interact with the DAN (Differential Screening-selected Gene Aberrative in Neuroblastoma) family proteins. The DAN family, characterized by its cystine knot structure, consists of secreted glycoproteins that regulate the activity of specific members of the TGF-β (Transforming Growth Factor Beta) superfamily, particularly by inhibiting signaling pathways. These proteins are essential modulators of growth factors that influence cellular processes such as proliferation and differentiation. NBL1 (Neuroblastoma Suppressor of Tumorigenicity 1) is a key gene within this family and was one of the first members identified. It encodes a protein that binds and neutralizes certain members of the BMP (Bone Morphogenetic Protein) family, thereby inhibiting their function in cellular signaling.
The inhibition of BMP signaling through DAN family proteins like NBL1 can have a broad impact on cellular processes due to BMP's role in regulating growth, development, and differentiation. DAN inhibitors target the structural interactions between the cystine knot motifs in the DAN protein and the BMP ligands, effectively blocking the downstream signaling pathways. This inhibition is critical in maintaining proper cellular homeostasis and ensuring the appropriate responses to growth factors. The mechanism of DAN inhibitors centers on their ability to prevent BMP ligands from binding to their receptors, modulating the effects that these ligands would otherwise have on cells.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor, potentially affecting the cell cycle and indirectly influencing DAN activity. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Another CDK4/6 inhibitor, similar to Palbociclib, it may impact the cell cycle pathways. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Inhibits CDK4/6, potentially altering cell cycle progression and indirectly affecting DAN signaling. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
A MEK inhibitor, which might indirectly affect DAN-related pathways in neuroblastoma. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Another MEK inhibitor, potentially influencing pathways associated with DAN. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Targets BRAF, which may be involved in pathways relevant to DAN's role in neuroblastoma. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $138.00 $255.00 $273.00 $403.00 $12240.00 | 6 | |
A BRAF inhibitor, potentially affecting signaling pathways related to DAN. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
An EGFR inhibitor, could indirectly affect cell signaling pathways relevant to DAN. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Another EGFR inhibitor, potentially altering signaling pathways associated with DAN. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple tyrosine kinases, potentially influencing DAN-related signaling. |